Fractyl Health Q3 net loss $45.6M; Revita post-GLP-1 weight maintenance data positive

FRACTYL HEALTH, INC.

2025-Q3 EPS reported -$1.79 vs consensus -$0.32 ▼ miss (-455.4%)

Net loss of $45.6M includes $23.5M non-cash warrant fair-value change; operating expenses down $1.1M YoY.
R&D spend $17.5M vs $19.0M year-ago; SG&A $5.2M vs $4.8M.
Cash $77.7M at Sep 30 2025; $83M in August/September offerings extend runway into early 2027.
REMAIN-1 Midpoint Cohort met endpoint: Revita patients lost 2.5% additional weight vs 10% regain for sham (p=0.014).
REMAIN-1 Pivotal enrollment >60% randomized; 6-month primary data expected H2 2026 with potential PMA filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.